CRDF / Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance

Cardiff Oncology, Inc. (NASDAQ:CRDF ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Kiki Patel - IR, Gilmartin Gro more_horizontal

Cardiff Oncology (CRDF) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined wit more_horizontal

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to los more_horizontal

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 20% and 70.67%, respectively, for the quarter ended December 2022. Do the numbers more_horizontal

SAN DIEGO , Feb. 27, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a more_horizontal

SAN DIEGO , Nov. 21, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to more_horizontal

Today, we circle back on small developmental concern Cardiff Oncology for the first time since the fourth quarter of 2021. The company's primary drug more_horizontal

Cardiff Oncology started taking a beating from the early days of the biotech bear market, in September 2021. The company is the first to correctly tar more_horizontal